These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36811208)

  • 21. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
    Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
    J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
    Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
    Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
    J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
    Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
    Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K
    J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
    Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T
    Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8+ T Cells and PD-L1 Expression as Prognostic Indicators in a Low Prevalence of HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Atipas K; Laokulrath N; Petsuksiri J; Ratanaprasert N; Pongsapich W
    Curr Oncol; 2023 Jan; 30(2):1450-1460. PubMed ID: 36826072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma.
    Kujan O; Agag M; Smaga M; Vaishnaw Y; Idrees M; Shearston K; Farah CS
    Pathology; 2022 Jun; 54(4):409-416. PubMed ID: 34872754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas.
    Škuciová V; Drahošová S; Výbohová D; Cígerová V; Adamkov M
    Pathol Res Pract; 2020 Sep; 216(9):153071. PubMed ID: 32825944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab.
    Kuba K; Inoue H; Matsumura S; Enoki Y; Kogashiwa Y; Ebihara Y; Nakahira M; Yamazaki T; Yasuda M; Kaira K; Kagamu H; Sugasawa M
    Sci Rep; 2022 Dec; 12(1):22557. PubMed ID: 36581686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed Death Ligand 1 (PD-L1) Expression and CD8 + Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy.
    Ordner J; Gutierrez Amezcua JM; Marcus A; Shukla PS
    Int J Gynecol Pathol; 2023 Jul; 42(4):364-375. PubMed ID: 35639400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
    Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
    Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classification of gallbladder cancer by assessment of CD8
    Lin J; Long J; Wan X; Chen J; Bai Y; Wang A; Yang X; Wu Y; Robson SC; Sang X; Zhao H
    BMC Cancer; 2018 Jul; 18(1):766. PubMed ID: 30055582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.